NHS Greater Glasgow & Clyde Area Drug and Therapeutics Committee
Greater Glasgow and Clyde Medicines
Medicines Update

LHRH agonists for Prostate Cancer

LHRH agonists have an important role in the management of prostate cancer.  Within NHSGGC, leuprorelin (Prostap® DCS brand) is the medicine of choice for new patients where castration therapy with an LHRH agonist is indicated for prostate cancer.

Care is required when choosing the item on prescribing systems to avoid confusion with the other brand of leuprorelin (Lutrate®). Refer to Medicines Update Primary Care.

Prostap® DCS is available as a monthly (Prostap® SR DCS) and 3 monthly (Prostap® 3 DCS) preparation.  It is important to ensure that the preparation prescribed and dispensed aligns to the frequency of administration. The table below provides an overview of leuprorelin products available.  It should be noted that Prostap® SR DCS and Prostap® 3 DCS are the medicines of choice. Patients are usually moved from the monthly preparation (Prostap® SR DCS) to the 3 monthly preparation (Prostap® 3 DCS) for subsequent injections if well tolerated.

(If viewing table on a mobile device switch to landscape)

Product name  Strength Form Frequency of administration Sharp safe device? Comment
Prostap® SR DCS Leuprorelin acetate 3.75mg Pre-filled disposable syringe (dual chamber) Monthly Yes Medicine of choice
Prostap® 3 DCS Leuprorelin acetate 11.25mg Pre-filled disposable syringe (dual chamber) 3 monthly Yes Medicine of choice
Lutrate® 1 month depot Leuprorelin acetate 3.75mg Powder and solvent for injection vials Monthly No Non-formulary
Lutrate® 3 month depot Leuprorelin acetate 22.5mg Powder and solvent for injection vials 3 monthly No Non-formulary

Learning Points

  • All healthcare professionals involved should take responsibility for LHRH agonist therapy.

Prescribing: prescribe by brand to reduce the risk of errors and check the dosing schedule at each prescribing encounter -  is the interval appropriate?

Supply: where possible, pharmacists should verify the time since the last preparation was supplied/administered - is the interval appropriate?

Administration:  nurses should verify at the point of administration when the medicine was last administered - is the interval appropriate?

  • Transfer of information from acute: prescribers and pharmacists should ensure information is added to the IDL regarding the type of preparation and date of administration whilst in hospital


Published 24/01/18